Barclays PLC购买了IVERIC Bio, Inc. (NASDAQ:ISEE)316,278股股票

Barclays PLC boosted its position in shares of  IVERIC bio, Inc. (NASDAQ:ISEE) by 2,216.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 330,550 shares of the company's stock after purchasing an additional 316,278 shares during the quarter. Barclays PLC owned about 0.28% of IVERIC bio worth $5,930,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ISEE. State Street Corp grew its position in shares of  IVERIC bio by 48.3% during the 2nd quarter. State Street Corp now owns 8,733,590 shares of the company's stock worth $84,017,000 after buying an additional 2,843,747 shares during the period.  Vanguard Group Inc. grew its position in shares of  IVERIC bio by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 5,778,729 shares of the company's stock worth $97,255,000 after buying an additional 99,606 shares during the period.  Deerfield Management Company L.P. Series C grew its position in shares of  IVERIC bio by 6.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,214,000 shares of the company's stock worth $50,159,000 after buying an additional 322,004 shares during the period.  Deutsche Bank AG grew its position in shares of  IVERIC bio by 2,234.4% during the 2nd quarter. Deutsche Bank AG now owns 2,421,322 shares of the company's stock worth $23,294,000 after buying an additional 2,317,598 shares during the period.  Finally, Commodore Capital LP grew its position in shares of  IVERIC bio by 8.8% in the 2nd quarter. Commodore Capital LP now owns 2,409,961 shares of the company's stock valued at $23,184,000 after purchasing an additional 195,000 shares during the period.

 Get IVERIC bio alerts:  

Analyst Ratings Changes

ISEE has been the subject of several research analyst reports. StockNews.com upgraded IVERIC bio to a "sell" rating in a research report on Wednesday, October 5th. Jefferies Financial Group lowered IVERIC bio from a "buy" rating to a "hold" rating and decreased their price objective for the company from $30.00 to $20.00 in a research report on Thursday, November 10th. B. Riley upgraded IVERIC bio from a "sell" rating to a "neutral" rating in a research report on Monday, October 17th. Finally, HC Wainwright boosted their price objective on IVERIC bio from $26.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, November 4th. One research analyst  has rated the stock with a sell rating, two have assigned  a hold rating and seven have issued  a buy rating to the company. According to MarketBeat.com, IVERIC bio currently has a consensus rating of "Moderate Buy" and an average target price of $26.20.

Insider Activity at IVERIC bio

In other IVERIC bio news, COO Keith Westby sold 72,916 shares of the stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $23.92, for a total transaction of $1,744,150.72. Following the transaction, the chief operating officer now owns 69,128 shares in the company, valued at approximately $1,653,541.76. In other IVERIC bio news, SVP Christopher Paul Simms sold 2,368 shares of the stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $20.06, for a total transaction of $47,502.08. Following the transaction, the senior vice president now owns 32,429 shares in the company, valued at approximately $650,525.74. Also, COO Keith Westby sold 72,916 shares of the stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $23.92, for a total value of $1,744,150.72. Following the transaction, the chief operating officer now owns 69,128 shares in the company, valued at approximately $1,653,541.76. In the last quarter, insiders have sold 201,050 shares of company stock worth $4,545,066. Company insiders own  2.70% of the company's stock.  

IVERIC bio Stock Up 3.7 %

ISEE opened at $22.65 on Friday. IVERIC bio, Inc. has a 1-year low of $8.85 and a 1-year high of $24.33. The stock's fifty day simple moving average is $21.21 and its 200 day simple moving average is $17.95. The company has a current ratio of 13.40, a quick ratio of 13.40 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.73 billion, a PE ratio of -16.90 and a beta of 1.05.

IVERIC bio (NASDAQ:ISEE) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05.  As a group, research analysts expect that  IVERIC bio, Inc. will post -1.43 earnings per share for the current year.

About IVERIC bio

IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.